The European SGLT2 inhibitor market is booming, projected to reach €2.54 billion by 2033 with a 9.1% CAGR. This in-depth analysis explores market drivers, trends, and key players like Janssen, Eli Lilly, and AstraZeneca, focusing on drugs like Invokana, Jardiance, and Farxiga. Discover the latest insights and future market forecasts.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.